USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has launched a global registration, phase II clinical trial investigating the efficacy of a potential new breast cancer therapy called ARX788.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe